In notable events, Sanofi is facing legal action from Texas for allegedly 'bribing' providers to increase drug prescriptions. Various claims of illegal kickbacks and practices have embroiled Sanofi in the past weeks. In leadership alterations, the company announced a change in senior management, removing CEO Paul Hudson and appointing Belén Garijo as his successor, marking the first female to assume this critical position. Furthermore, the company has expressed commitment to its workforce, stating plans to expand its India GCC and increase its employee base to over 4,500.
A spotlight is also on Sanofi's partnership with Teva, producing promising Phase IIb trial results for duvakitug in managing ulcerative colitis and Crohn’s disease. Meanwhile, the company failed to develop a next-gen mRNA seasonal flu vaccine and GCS inhibitor for Fabry disease while finding success in Gaucher disease. Financially, Sanofi's shares have seen fluctuations, experiencing a drop post-CEO change. Finally, the company expands its biotech pipeline with two billion-dollar deals and pushes forward with adult vaccines in a $2.2 billion deal with Dynavax.
Sanofi News Analytics from Fri, 06 Jun 2025 07:00:00 GMT to Sat, 21 Feb 2026 08:38:25 GMT - Rating -4 - Innovation -6 - Information 2 - Rumor 2
